Recurrent platinum sensitive primary peritoneal cancer

Drug	Drug Name	Drug Description
DB00112	Bevacizumab	A monoclonal anti-vascular endothelial growth factor antibody used in combination with antineoplastic agents for the treatment of many types of cancer.
DB09074	Olaparib	A poly (ADP-ribose) polymerase (PARP) inhibitor used to treat ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer.

Drug	Drug Name	Target	Type
DB00112	Bevacizumab	Vascular endothelial growth factor A	target
DB00112	Bevacizumab	Complement C1q subcomponent subunit A	target
DB00112	Bevacizumab	Complement C1q subcomponent subunit B	target
DB00112	Bevacizumab	Complement C1q subcomponent subunit C	target
DB00112	Bevacizumab	Low affinity immunoglobulin gamma Fc region receptor III-A	target
DB00112	Bevacizumab	Low affinity immunoglobulin gamma Fc region receptor II-a	target
DB00112	Bevacizumab	Low affinity immunoglobulin gamma Fc region receptor II-b	target
DB00112	Bevacizumab	Low affinity immunoglobulin gamma Fc region receptor II-c	target
DB00112	Bevacizumab	High affinity immunoglobulin gamma Fc receptor I	target
DB09074	Olaparib	Poly [ADP-ribose] polymerase 1	target
DB09074	Olaparib	Cytochrome P450 3A4	enzyme
DB09074	Olaparib	Cytochrome P450 2B6	enzyme
DB09074	Olaparib	Poly [ADP-ribose] polymerase 2	target
DB09074	Olaparib	Poly [ADP-ribose] polymerase 3	target
DB09074	Olaparib	Cytochrome P450 3A5	enzyme
DB09074	Olaparib	P-glycoprotein 1	transporter
DB09074	Olaparib	ATP-binding cassette sub-family G member 2	transporter
DB09074	Olaparib	Aldo-keto reductase family 1 member C3	target
DB09074	Olaparib	UDP-glucuronosyltransferase 1-1	enzyme
DB09074	Olaparib	Serum albumin	carrier
DB09074	Olaparib	Alpha-1-acid glycoprotein 1	carrier

Drug	Drug Name	Phase	Status	Count